TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Capricor Therapeutics ( (CAPR) ) just unveiled an update.
On December 3, 2025, Capricor Therapeutics provided an update on the top-line results from its HOPE-3 Phase 3 trial during a conference call. The trial, which involved 106 patients, focused on the efficacy and safety of Deramiocel for treating Duchenne muscular dystrophy. The results indicated significant improvements in skeletal muscle function and cardiac endpoints, confirming the findings of previous trials. The trial met its primary and key secondary endpoints, demonstrating a favorable long-term safety profile and sustained efficacy over four years. This development could potentially enhance Capricor’s position in the biotechnology industry and provide new treatment options for patients with high unmet needs.
The most recent analyst rating on (CAPR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Capricor Therapeutics stock, see the CAPR Stock Forecast page.
Spark’s Take on CAPR Stock
According to Spark, TipRanks’ AI Analyst, CAPR is a Neutral.
Capricor Therapeutics’ overall stock score is primarily impacted by its financial struggles, including persistent losses and cash flow issues. While technical analysis and earnings call insights provide some positive outlooks, the valuation challenges and regulatory hurdles weigh heavily on the stock’s attractiveness.
To see Spark’s full report on CAPR stock, click here.
More about Capricor Therapeutics
Capricor Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies from bench to bedside. The company is involved in the development of investigational candidates like Deramiocel and the StealthX vaccine, which are not yet approved for commercial use. Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for Duchenne muscular dystrophy in the United States and Japan with Nippon Shinyaku Co., Ltd., subject to regulatory approval.
Average Trading Volume: 1,595,651
Technical Sentiment Signal: Sell
Current Market Cap: $304M
See more data about CAPR stock on TipRanks’ Stock Analysis page.